Market capitalization | €10.61b |
Enterprise Value | €22.72b |
PER (TTM) P/E ratio | 21.94 |
EV/FCF (TTM) EV/FCF | 11.73 |
EV/Sales (TTM) EV/Sales | 1.17 |
P/S ratio (TTM) P/S ratio | 0.54 |
P/B ratio (TTM) P/B ratio | 0.76 |
Dividend yield | 3.29% |
Last dividend (FY23) | €1.19 |
As a Free StocksGuide user, you can view scores for all 6,945 stocks worldwide.
23 Analysts have issued a Fresenius Medical Care forecast:
23 Analysts have issued a Fresenius Medical Care forecast:
Dec '23 |
+/-
%
|
||
Net Profit | 499 499 |
26%
26%
|
|
Depreciation and Amortization | 1,613 1,613 |
6%
6%
|
|
Stock Compensation | - - |
-
|
|
Operating Cash Flow | 2,629 2,629 |
21%
21%
|
|
Investments | 711 711 |
8%
8%
|
|
Dividend Paid | 329 329 |
17%
17%
|
|
Free Cash Flow | 1,944 1,944 |
35%
35%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Fresenius Medical Care AG & Co. KGaA engages in the provision of products and services for patients with chronic kidney failure. It also develop and manufacture a variety of health care products, which includes dialysis and non-dialysis products. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.
Head office | Germany |
CEO | Helen Giza |
Employees | 119,845 |
Founded | 1996 |
Website | www.freseniusmedicalcare.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.